Beam Therapeutics

Beam Therapeutics

A synthetic biology company using CRISPR to develop a portfolio of genetic medicines.

All edits by  Rahul Duggal 

Edits on 12 Sep, 2019
Rahul Duggal
Rahul Duggal approved a suggestion from Golden's AI on 12 Sep, 2019
Edits made to:
Article (+2/-2 characters)

On March 6, 2019 Beam therapeutics completed their series B funding round with $135 million in funding from F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, Omega Funds, Redmile Group, LLC, Cormorant Asset Management, GVGV, Altitude Life Science Ventures, and additional undisclosed investors.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.